Perturbation of Rb, p53, and Brca1 or Brca2 Cooperate in Inducing Metastatic Serous Epithelial Ovarian Cancer

被引:95
|
作者
Szabova, Ludmila [1 ]
Yin, Chaoying [4 ]
Bupp, Sujata [1 ]
Guerin, Theresa M. [1 ]
Schlomer, Jerome J. [1 ]
Householder, Deborah B. [1 ]
Baran, Maureen L. [1 ]
Yi, Ming [2 ]
Song, Yurong [3 ,4 ]
Sun, Wenping [2 ]
McDunn, Jonathan E. [5 ]
Martin, Philip L. [1 ]
Van Dyke, Terry [1 ,3 ,4 ]
Difilippantonio, Simone [1 ]
机构
[1] NCI Federick, Ctr Adv Preclin Res, SAIC, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA
[2] NCI Federick, Adv Biomed Comp Ctr, SAIC, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA
[3] NCI Frederick, Mouse Canc Genet Program, Frederick, MD USA
[4] Univ N Carolina, Dept Genet, Chapel Hill, NC USA
[5] Metabolon Inc, Durham, NC USA
关键词
MOUSE MODEL; CONDITIONAL INACTIVATION; FALLOPIAN-TUBE; PERITONEAL MESOTHELIOMA; PAPILLARY CARCINOMA; DISTANT METASTASES; MUTATIONS; INDUCTION; WOMEN; P130;
D O I
10.1158/0008-5472.CAN-11-3834
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The majority of human high-grade serous epithelial ovarian cancer (SEOC) is characterized by frequent mutations in p53 and alterations in the RB and FOXM1 pathways. A subset of human SEOC harbors a combination of germline and somatic mutations as well as epigenetic dysfunction for BRCA1/2. Using Cre-conditional alleles and intrabursal induction by Cre-expressing adenovirus in genetically engineered mice, we analyzed the roles of pathway perturbations in epithelial ovarian cancer initiation and progression. Inactivation of RB-mediated tumor suppression induced surface epithelial proliferation with progression to stage I carcinoma. Additional biallelic inactivation and/or missense p53 mutation in the presence or absence of Brca1/2 caused progression to stage IV disease. As in human SEOC, mice developed peritoneal carcinomatosis, ascites, and distant metastases. Unbiased gene expression and metabolomic profiling confirmed that Rb, p53, and Brca1/2-triple mutant tumors aligned with human SEOC, and not with other intraperitoneal cancers. Together, our findings provide a novel resource for evaluating disease etiology and biomarkers, therapeutic evaluation, and improved imaging strategies in epithelial ovarian cancer. Cancer Res; 72(16); 4141-53. (C) 2012 AACR.
引用
收藏
页码:4141 / 4153
页数:13
相关论文
共 50 条
  • [21] Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations
    Ganguly, Shuvadeep
    Gogia, Ajay
    LANCET ONCOLOGY, 2022, 23 (07): : E314 - E314
  • [22] Contraception as chemoprevention of ovarian cancer in BRCA1 and BRCA2 women
    Loizzi, Vera
    Cerbone, Marco
    Arezzo, Francesca
    Silvestris, Erica
    Damiani, Gianluca Raffaello
    Cazzato, Gerardo
    Cicinelli, Ettore
    Cormio, Gennaro
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2024, 23 (02): : 277 - 286
  • [23] Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes
    Pietragalla, Antonella
    Arcieri, Martina
    Marchetti, Claudia
    Scambia, Giovanni
    Fagotti, Anna
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (11) : 1803 - 1810
  • [24] Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer
    Ramus, Susan J.
    Harrington, Patricia A.
    Pye, Carole
    DiCioccio, Richard A.
    Cox, Mark J.
    Garlinghouse-Jones, Kim
    Oakley-Girvan, Ingrid
    Jacobs, Ian J.
    Hardy, Richard M.
    Whittemore, Alice S.
    Ponder, Bruce A. J.
    Piver, M. Steven
    Pharoah, Paul D. P.
    Gayther, Simon A.
    HUMAN MUTATION, 2007, 28 (12) : 1207 - 1215
  • [25] Unwrapping the Implications of BRCA1 and BRCA2 Mutations in Ovarian Cancer
    Hyman, David M.
    Spriggs, David R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (04): : 408 - 410
  • [26] Screening for ovarian cancer in BRCA1/BRCA2 mutations carriers
    Synowiec, Agnieszka
    Wcislo, Gabriel
    Bodnar, Lubomir
    Gasowska-Bodnar, Agnieszka
    Szczylik, Cezary
    GINEKOLOGIA POLSKA, 2014, 85 (05) : 377 - 381
  • [27] BRCA1 and BRCA2 alterations in ovarian MMMT
    Geisler, JP
    Goodheart, MJ
    Buller, RE
    GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 774 - 774
  • [28] Cooperativity of Rb, Brca1, and p53 in Malignant Breast Cancer Evolution
    Kumar, Prashant
    Mukherjee, Malini
    Johnson, Jacob P. S.
    Patel, Milan
    Huey, Bing
    Albertson, Donna G.
    Simin, Karl
    PLOS GENETICS, 2012, 8 (11):
  • [29] BRCA1 and BRCA2 cancer risks
    Antoniou, Antonis C.
    Pharoah, Paul D. P.
    Easton, Douglas F.
    Evans, D. Gareth
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (20) : 3312 - 3313
  • [30] BRCA1 and BRCA2 in breast cancer
    Yang, XH
    Lippman, ME
    BREAST CANCER RESEARCH AND TREATMENT, 1999, 54 (01) : 1 - 10